149 related articles for article (PubMed ID: 35294527)
1. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
[TBL] [Abstract][Full Text] [Related]
3. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
7. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
8. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
9. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
[TBL] [Abstract][Full Text] [Related]
10. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
[TBL] [Abstract][Full Text] [Related]
11. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
[TBL] [Abstract][Full Text] [Related]
14. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of
Guo L; Wang X; Xu B; Lang R; Hu B
Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
[No Abstract] [Full Text] [Related]
16. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
[TBL] [Abstract][Full Text] [Related]
17. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
18. CTNNB1 Mutations and Estrogen Receptor Expression in Neuromuscular Choristoma and Its Associated Fibromatosis.
Carter JM; Howe BM; Hawse JR; Giannini C; Spinner RJ; Fritchie KJ
Am J Surg Pathol; 2016 Oct; 40(10):1368-74. PubMed ID: 27259010
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
Nishida Y; Hamada S; Kawai A; Kunisada T; Ogose A; Matsumoto Y; Ae K; Toguchida J; Ozaki T; Hirakawa A; Motoi T; Sakai T; Kobayashi E; Gokita T; Okamoto T; Matsunobu T; Shimizu K; Koike H
Cancer Sci; 2020 Aug; 111(8):2935-2942. PubMed ID: 32539220
[TBL] [Abstract][Full Text] [Related]
20. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.
Trautmann M; Rehkämper J; Gevensleben H; Becker J; Wardelmann E; Hartmann W; Grünewald I; Huss S
Sci Rep; 2020 Feb; 10(1):3368. PubMed ID: 32099073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]